A randomized, double-blinded, placebo-controlled trial will be conducted to evaluate
vortioxetine, an antidepressant with established pro-cognitive properties, for the treatment
of cognitive deficits which develop during or after an infection consistent with COVID-19,
continue for more than 12 weeks and are not explained by an alternative diagnosis (i.e.,
post-COVID-19 syndrome). Participants will receive vortioxetine (10-20 mg) or placebo for 8
weeks. Changes in cognitive functioning from baseline to endpoint (week 8) will be assessed
via the Digit Symbol Substitution Test (DSST).